2023-11-07 11:07:00
The French pharmaceutical group Sanofi is under investigation by the National Financial Prosecutor’s Office (PNF) for price manipulation and dissemination of false or misleading information in its financial communication around its flagship drug, Dupixent. The information, revealed on Tuesday November 7 by the investigative media La Lettre, was confirmed by a judicial source to Archyde.com.
Available since 2017, the latter is a monoclonal antibody used for inflammatory diseases such as asthma and atopic dermatitis. Its use then expanded to diseases of the esophagus. More than 750,000 people around the world today use this medication, which is marketed in around thirty countries. At the same time, sales of Dupixent have exploded from 2 billion euros at the end of 2019 to 11 billion euros in 2023 according to statements by Sanofi CEO Paul Hudson on the occasion of the presentation of the quarterly results of group last October.
VOS INDICES
source
Sanofi says it is not aware
Contacted by Archyde.com, Sanofi said it was “not aware of any preliminary investigation by the National Financial Prosecutor’s Office into its 2017 accounts or otherwise.” The company adds that “as a listed company, the financial information that Sanofi publishes is accurate, precise and sincere, and is also duly audited by two auditing firms. Sanofi reserves the right to take legal action once morest any false or defamatory allegations.
1699435088
#Sanofi #targeted #PNF #investigation #suspicion #price #manipulation #Dupixent
